BiotechTube

Deferasirox (ICL670)

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Iron Overload

Conditions

Iron Overload, Hereditary Hemochromatosis

Trial Timeline

Aug 1, 2006 → Mar 1, 2009

NCT ID
NCT00395629

About Deferasirox (ICL670)

Deferasirox (ICL670) is a phase 1/2 stage product being developed by Novartis for Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT00395629. Target conditions include Iron Overload, Hereditary Hemochromatosis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT00631163Phase 2Completed
NCT00395629Phase 1/2Completed

Competing Products

20 competing products in Iron Overload

See all competitors
ProductCompanyStageHype Score
KER-047Keros TherapeuticsPhase 2
44
H. pylori treatmentEisaiPhase 2/3
65
DeferasiroxNovartisPhase 3
77
CSJ137 + PlaceboNovartisPhase 1
33
Deferasirox and DeferoxamineNovartisPhase 2
52
DeferasiroxNovartisPhase 2
52
ICL670NovartisPhase 2
52
DeferasiroxNovartisApproved
85
Deferasirox + DeferasiroxNovartisPhase 2/3
65
DesferasiroxNovartisApproved
85
DeferasiroxNovartisPhase 2
52
DeferasiroxNovartisPhase 3
77
Deferasirox dispersible tablet + Defearisox film-coated tabletNovartisPhase 2
52
deferasiroxNovartisApproved
85
ICL670NovartisApproved
85
DeferasiroxNovartisPhase 3
77
Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + DeferoxamineNovartisPhase 2
52
DeferasiroxNovartisApproved
85
Z-213 + Saccharated Ferric OxideZeria PharmaceuticalPhase 3
76
Z-213Zeria PharmaceuticalPhase 3
76

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85